Yanyan Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yanyan Zhao has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Feng Guo
Department of Endocrinology and Metabolism The First Affiliated Hospital of Zhengzhou University Zhengzhou China
9 shared publicationsGuijun Qin
Division of Endocrinology, Department of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
7 shared publicationsJiao Wang
Department of Endocrinology and Metabolism The First Affiliated Hospital of Zhengzhou University Zhengzhou China
7 shared publicationsYi Song
Department of Endocrinology and Metabolism The First Affiliated Hospital of Zhengzhou University Zhengzhou China
7 shared publicationsFengjuan Huang
Department of Endocrinology and Metabolic Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China
6 shared publicationsMengxing Pan
Department of Endocrinology and Metabolic Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China
6 shared publications
Latest Publications
- Open Access
- 27 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (47) , e17222
Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota‐Dependent Manner
Canagliflozin reduces albuminuria in patients with diabetic kidney disease (DKD) beyond its glucose‐lowering effect, but the mechanisms remain unclear. We analyzed 85 patients treated with canagliflozin and 85 controls over 26 weeks to explore whether the gut microbiome and its metabolites contribute to renoprotection. Canagliflozin remodeled the gut microbiota, notably enriching Roseburia intestinalis and increasing plasma melibiose levels. In mice, canagliflozin alleviated glomerular endothelial injury and albuminuria. Similar effects were replicated by fecal microbiota transplantation, Roseburia intestinalis , or melibiose administration. Mechanistically, melibiose bound to and activated glyoxalase 1, reduced methylglyoxal, and suppressed the AGE‐RAGE pathway, preserving glomerular endothelial integrity. Furthermore, oral melibiose precursor supplementation reduced albuminuria in patients with early‐stage DKD. These findings suggest the involvement of a gut‐kidney axis in the renoprotective effects of canagliflozin and indicate that melibiose may serve as a potential therapeutic strategy for DKD.
- 27 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (47) , e17222
Open AccessCanagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota‐Dependent Manner
Canagliflozin reduces albuminuria in patients with diabetic kidney disease (DKD) beyond its glucose‐lowering effect, but the mechanisms remain unclear. We analyzed 85 patients treated with canagliflozin and 85 controls over 26 weeks to explore whether the gut microbiome and its metabolites contribute to renoprotection. Canagliflozin remodeled the gut microbiota, notably enriching Roseburia intestinalis and increasing plasma melibiose levels. In mice, canagliflozin alleviated glomerular endothelial injury and albuminuria. Similar effects were replicated by fecal microbiota transplantation, Roseburia intestinalis , or melibiose administration. Mechanistically, melibiose bound to and activated glyoxalase 1, reduced methylglyoxal, and suppressed the AGE‐RAGE pathway, preserving glomerular endothelial integrity. Furthermore, oral melibiose precursor supplementation reduced albuminuria in patients with early‐stage DKD. These findings suggest the involvement of a gut‐kidney axis in the renoprotective effects of canagliflozin and indicate that melibiose may serve as a potential therapeutic strategy for DKD.
- Open Access
- 22 May 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Development and validation of a predictive model for hypothalamic obesity following craniopharyngioma resection
To analyze the risk factors for hypothalamic obesity (HO) after craniopharyngioma surgery, construct a predictive model and verify its efficacy. A retrospective analysis was conducted on 136 patients diagnosed with craniopharyngioma at The First Affiliated Hospital of Zhengzhou University between September 2018 and February 2024. Clinical and follow-up data were collected and split into training and validation cohorts (7: 3) randomly and divided into HO and non-HO groups post-surgery. Logistic regression was used to analyse risk factors for postoperative HO, and a prediction model was constructed and its efficacy was verified. In the training cohort, the preoperative body mass index (BMI), preoperative serum sodium, preoperative uric acid levels, postoperative calcium levels, the probability of intraoperative blood loss ≥ 100 ml and preoperative hypothalamic injury and T-type tumors were higher in HO group. Small tumors (< 5 cm³) were less frequent in HO group (all P < 0.05). Logistic regression analysis showed that preoperative high BMI and intraoperative blood loss ≥ 100 ml were independent risk factors for postoperative HO, while older age at onset and smaller tumor size were protective factors (all P < 0.05). The model developed from the training cohort showed that the area under the receiver operating characteristic curve (AUC) was 0.865(95%CI of 0.793 ~ 0.937), with a sensitivity of 79.5% and a specificity of 80.8%, the validation cohort had an AUC of 0.864(95%CI:0.744-0.983), with a sensitivity of 90.9% and a specificity of 72.2%. The calibration curve and Hosmer-Lemeshow test demonstrated that the predicted value of the model was in agreement with the observed values in both the training and verification cohorts (P > 0.05). Preoperative high BMI and intraoperative blood loss ≥ 100 ml are independent risk factors for HO after craniopharyngioma surgery. A predictive model based on preoperative BMI, age at onset, intraoperative blood loss, and tumor size shows potential for predicting the risk of postoperative HO, aiding in early identification for high-risk patients. Not applicable.
- 22 May 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Open AccessDevelopment and validation of a predictive model for hypothalamic obesity following craniopharyngioma resection
To analyze the risk factors for hypothalamic obesity (HO) after craniopharyngioma surgery, construct a predictive model and verify its efficacy. A retrospective analysis was conducted on 136 patients diagnosed with craniopharyngioma at The First Affiliated Hospital of Zhengzhou University between September 2018 and February 2024. Clinical and follow-up data were collected and split into training and validation cohorts (7: 3) randomly and divided into HO and non-HO groups post-surgery. Logistic regression was used to analyse risk factors for postoperative HO, and a prediction model was constructed and its efficacy was verified. In the training cohort, the preoperative body mass index (BMI), preoperative serum sodium, preoperative uric acid levels, postoperative calcium levels, the probability of intraoperative blood loss ≥ 100 ml and preoperative hypothalamic injury and T-type tumors were higher in HO group. Small tumors (< 5 cm³) were less frequent in HO group (all P < 0.05). Logistic regression analysis showed that preoperative high BMI and intraoperative blood loss ≥ 100 ml were independent risk factors for postoperative HO, while older age at onset and smaller tumor size were protective factors (all P < 0.05). The model developed from the training cohort showed that the area under the receiver operating characteristic curve (AUC) was 0.865(95%CI of 0.793 ~ 0.937), with a sensitivity of 79.5% and a specificity of 80.8%, the validation cohort had an AUC of 0.864(95%CI:0.744-0.983), with a sensitivity of 90.9% and a specificity of 72.2%. The calibration curve and Hosmer-Lemeshow test demonstrated that the predicted value of the model was in agreement with the observed values in both the training and verification cohorts (P > 0.05). Preoperative high BMI and intraoperative blood loss ≥ 100 ml are independent risk factors for HO after craniopharyngioma surgery. A predictive model based on preoperative BMI, age at onset, intraoperative blood loss, and tumor size shows potential for predicting the risk of postoperative HO, aiding in early identification for high-risk patients. Not applicable.
- Open Access
- 17 July 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1379821
The role of metabolic memory in diabetic kidney disease: identification of key genes and therapeutic targets
Diabetic kidney disease (DKD) is characterized by complex pathogenesis and poor prognosis; therefore, an exploration of novel etiological factors may be beneficial. Despite glycemic control, the persistence of transient hyperglycemia still induces vascular complications due to metabolic memory. However, its contribution to DKD remains unclear. Using single-cell RNA sequencing data from the Gene Expression Omnibus (GEO) database, we clustered 12 cell types and employed enrichment analysis and a cell‒cell communication network. Fibrosis, a characteristic of DKD, was found to be associated with metabolic memory. To further identify genes related to metabolic memory and fibrosis in DKD, we combined the above datasets from humans with a rat renal fibrosis model and mouse models of metabolic memory. After overlapping, NDRG1, NR4A1, KCNC4 and ZFP36 were selected. Pharmacology analysis and molecular docking revealed that pioglitazone and resveratrol were possible agents affecting these hub genes. Based on the ex vivo results, NDRG1 was selected for further study. Knockdown of NDRG1 reduced TGF-β expression in human kidney-2 cells (HK-2 cells). Compared to that in patients who had diabetes for more than 10 years but not DKD, NDRG1 expression in blood samples was upregulated in DKD patients. In summary, NDRG1 is a key gene involved in regulating fibrosis in DKD from a metabolic memory perspective. Bioinformatics analysis combined with experimental validation provided reliable evidence for identifying metabolic memory in DKD patients.
- 17 July 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1379821
Open AccessThe role of metabolic memory in diabetic kidney disease: identification of key genes and therapeutic targets
Diabetic kidney disease (DKD) is characterized by complex pathogenesis and poor prognosis; therefore, an exploration of novel etiological factors may be beneficial. Despite glycemic control, the persistence of transient hyperglycemia still induces vascular complications due to metabolic memory. However, its contribution to DKD remains unclear. Using single-cell RNA sequencing data from the Gene Expression Omnibus (GEO) database, we clustered 12 cell types and employed enrichment analysis and a cell‒cell communication network. Fibrosis, a characteristic of DKD, was found to be associated with metabolic memory. To further identify genes related to metabolic memory and fibrosis in DKD, we combined the above datasets from humans with a rat renal fibrosis model and mouse models of metabolic memory. After overlapping, NDRG1, NR4A1, KCNC4 and ZFP36 were selected. Pharmacology analysis and molecular docking revealed that pioglitazone and resveratrol were possible agents affecting these hub genes. Based on the ex vivo results, NDRG1 was selected for further study. Knockdown of NDRG1 reduced TGF-β expression in human kidney-2 cells (HK-2 cells). Compared to that in patients who had diabetes for more than 10 years but not DKD, NDRG1 expression in blood samples was upregulated in DKD patients. In summary, NDRG1 is a key gene involved in regulating fibrosis in DKD from a metabolic memory perspective. Bioinformatics analysis combined with experimental validation provided reliable evidence for identifying metabolic memory in DKD patients.
- Top Cited PapersOpen Access
- 26 May 2024
- Published by Springer Nature in Molecular Medicine
- Vol. 30 (1) , 1-19
An update on chronic complications of diabetes mellitus: from molecular mechanisms to therapeutic strategies with a focus on metabolic memory
Diabetes mellitus, a chronic metabolic disease, often leads to numerous chronic complications, significantly contributing to global morbidity and mortality rates. High glucose levels trigger epigenetic modifications linked to pathophysiological processes like inflammation, immunity, oxidative stress, mitochondrial dysfunction, senescence and various kinds of cell death. Despite glycemic control, transient hyperglycemia can persistently harm organs, tissues, and cells, a latent effect termed "metabolic memory" that contributes to chronic diabetic complications. Understanding metabolic memory's mechanisms could offer a new approach to mitigating these complications. However, key molecules and networks underlying metabolic memory remain incompletely understood. This review traces the history of metabolic memory research, highlights its key features, discusses recent molecules involved in its mechanisms, and summarizes confirmed and potential therapeutic compounds. Additionally, we outline in vitro and in vivo models of metabolic memory. We hope this work will inform future research on metabolic memory's regulatory mechanisms and facilitate the development of effective therapeutic compounds to prevent diabetic complications.
- 26 May 2024
- Published by Springer Nature in Molecular Medicine
- Vol. 30 (1) , 1-19
Top Cited PapersOpen AccessAn update on chronic complications of diabetes mellitus: from molecular mechanisms to therapeutic strategies with a focus on metabolic memory
Diabetes mellitus, a chronic metabolic disease, often leads to numerous chronic complications, significantly contributing to global morbidity and mortality rates. High glucose levels trigger epigenetic modifications linked to pathophysiological processes like inflammation, immunity, oxidative stress, mitochondrial dysfunction, senescence and various kinds of cell death. Despite glycemic control, transient hyperglycemia can persistently harm organs, tissues, and cells, a latent effect termed "metabolic memory" that contributes to chronic diabetic complications. Understanding metabolic memory's mechanisms could offer a new approach to mitigating these complications. However, key molecules and networks underlying metabolic memory remain incompletely understood. This review traces the history of metabolic memory research, highlights its key features, discusses recent molecules involved in its mechanisms, and summarizes confirmed and potential therapeutic compounds. Additionally, we outline in vitro and in vivo models of metabolic memory. We hope this work will inform future research on metabolic memory's regulatory mechanisms and facilitate the development of effective therapeutic compounds to prevent diabetic complications.
- 7 April 2024
- Published by Springer Nature in Acta Diabetologica
- Vol. 61 (8) , 963-974
Associations between life’s essential 8 and metabolic health among us adults: insights of NHANES from 2005 to 2018
Background Metabolic unhealth (MUH) is closely associated with cardiovascular disease (CVD). Life’s Essential 8 (LE8), a recently updated cardiovascular health (CVH) assessment, has some overlapping indicators with MUH but is more comprehensive and complicated than MUH. Given the close relationship between them, it is important to compare these two measurements. Methods This population-based cross-sectional survey included 20- to 80-year-old individuals from 7 National Health and Nutrition Examination Survey (NHANES) cycles between 2005 and 2018. Based on the parameters provided by the American Heart Association, the LE8 score (which ranges from 0 to 100) was used to classify CVH into three categories: low (0–49), moderate (50–79), and high (80–100). The MUH status was evaluated by blood glucose, blood pressure, and blood lipids. The associations were assessed by multivariable regression analysis, subgroup analysis, restricted cubic spline models, and sensitivity analysis. Results A total of 22,582 participants were enrolled (median of age was 45 years old), among them, 11,127 were female (weighted percentage, 49%) and 16,595 were classified as MUH (weighted percentage, 73.5%). The weighted median LE8 scores of metabolic health (MH) and MUH individuals are 73.75 and 59.38, respectively. Higher LE8 scores were linked to lower risks of MUH (odds ratio [OR] for every 10 scores increase, 0.53; 95% CI 0.51–0.55), and a nonlinear dose–response relationship was seen after the adjustment of potential confounders. This negative correlation between LE8 scores, and MUH was strengthened among elderly population. Conclusions Higher LE8 and its subscales scores were inversely and nonlinearly linked with the lower presence of MUH. MUH is consistent with LE8 scores, which can be considered as an alternative indicator when it is difficult to collect the information of health behaviors.
- 7 April 2024
- Published by Springer Nature in Acta Diabetologica
- Vol. 61 (8) , 963-974
Associations between life’s essential 8 and metabolic health among us adults: insights of NHANES from 2005 to 2018
Background Metabolic unhealth (MUH) is closely associated with cardiovascular disease (CVD). Life’s Essential 8 (LE8), a recently updated cardiovascular health (CVH) assessment, has some overlapping indicators with MUH but is more comprehensive and complicated than MUH. Given the close relationship between them, it is important to compare these two measurements. Methods This population-based cross-sectional survey included 20- to 80-year-old individuals from 7 National Health and Nutrition Examination Survey (NHANES) cycles between 2005 and 2018. Based on the parameters provided by the American Heart Association, the LE8 score (which ranges from 0 to 100) was used to classify CVH into three categories: low (0–49), moderate (50–79), and high (80–100). The MUH status was evaluated by blood glucose, blood pressure, and blood lipids. The associations were assessed by multivariable regression analysis, subgroup analysis, restricted cubic spline models, and sensitivity analysis. Results A total of 22,582 participants were enrolled (median of age was 45 years old), among them, 11,127 were female (weighted percentage, 49%) and 16,595 were classified as MUH (weighted percentage, 73.5%). The weighted median LE8 scores of metabolic health (MH) and MUH individuals are 73.75 and 59.38, respectively. Higher LE8 scores were linked to lower risks of MUH (odds ratio [OR] for every 10 scores increase, 0.53; 95% CI 0.51–0.55), and a nonlinear dose–response relationship was seen after the adjustment of potential confounders. This negative correlation between LE8 scores, and MUH was strengthened among elderly population. Conclusions Higher LE8 and its subscales scores were inversely and nonlinearly linked with the lower presence of MUH. MUH is consistent with LE8 scores, which can be considered as an alternative indicator when it is difficult to collect the information of health behaviors.
- 18 January 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (4) , 738-754
Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns
Aims/hypothesis Sodium–glucose co-transporter 2 (SGLT2) inhibitors (SGLT2i) are antihyperglycaemic drugs that protect the kidneys of individuals with type 2 diabetes mellitus. However, the underlying mechanisms mediating the renal benefits of SGLT2i are not fully understood. Considering the fuel switches that occur during therapeutic SGLT2 inhibition, we hypothesised that SGLT2i induce fasting-like and aestivation-like metabolic patterns, both of which contribute to the regulation of metabolic reprogramming in diabetic kidney disease (DKD). Methods Untargeted and targeted metabolomics assays were performed on plasma samples from participants with type 2 diabetes and kidney disease (n=35, 11 women) receiving canagliflozin (CANA) 100 mg/day at baseline and 12 week follow-up. Next, a systematic snapshot of the effect of CANA on key metabolites and pathways in the kidney was obtained using db/db mice. Moreover, the effects of glycine supplementation in db/db mice and human proximal tubular epithelial cells (human kidney-2 [HK-2]) cells were studied. Results Treatment of DKD patients with CANA for 12 weeks significantly reduced HbA1c from a median (interquartile range 25–75%) of 49.0 (44.0–57.0) mmol/mol (7.9%, [7.10–9.20%]) to 42.2 (39.7–47.7) mmol/mol (6.8%, [6.40–7.70%]), and reduced urinary albumin/creatinine ratio from 67.8 (45.9–159.0) mg/mmol to 47.0 (26.0–93.6) mg/mmol. The untargeted metabolomics assay showed downregulated glycolysis and upregulated fatty acid oxidation. The targeted metabolomics assay revealed significant upregulation of glycine. The kidneys of db/db mice undergo significant metabolic reprogramming, with changes in sugar, lipid and amino acid metabolism; CANA regulated the metabolic reprogramming in the kidneys of db/db mice. In particular, the pathways for glycine, serine and threonine metabolism, as well as the metabolite of glycine, were significantly upregulated in CANA-treated kidneys. Glycine supplementation ameliorated renal lesions in db/db mice by inhibiting food intake, improving insulin sensitivity and reducing blood glucose levels. Glycine supplementation improved apoptosis of human proximal tubule cells via the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway. Conclusions/interpretation In conclusion, our study shows that CANA ameliorates DKD by inducing fasting-like and aestivation-like metabolic patterns. Furthermore, DKD was ameliorated by glycine supplementation, and the beneficial effects of glycine were probably due to the activation of the AMPK/mTOR pathway. Graphical Abstract
- 18 January 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (4) , 738-754
Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns
Aims/hypothesis Sodium–glucose co-transporter 2 (SGLT2) inhibitors (SGLT2i) are antihyperglycaemic drugs that protect the kidneys of individuals with type 2 diabetes mellitus. However, the underlying mechanisms mediating the renal benefits of SGLT2i are not fully understood. Considering the fuel switches that occur during therapeutic SGLT2 inhibition, we hypothesised that SGLT2i induce fasting-like and aestivation-like metabolic patterns, both of which contribute to the regulation of metabolic reprogramming in diabetic kidney disease (DKD). Methods Untargeted and targeted metabolomics assays were performed on plasma samples from participants with type 2 diabetes and kidney disease (n=35, 11 women) receiving canagliflozin (CANA) 100 mg/day at baseline and 12 week follow-up. Next, a systematic snapshot of the effect of CANA on key metabolites and pathways in the kidney was obtained using db/db mice. Moreover, the effects of glycine supplementation in db/db mice and human proximal tubular epithelial cells (human kidney-2 [HK-2]) cells were studied. Results Treatment of DKD patients with CANA for 12 weeks significantly reduced HbA1c from a median (interquartile range 25–75%) of 49.0 (44.0–57.0) mmol/mol (7.9%, [7.10–9.20%]) to 42.2 (39.7–47.7) mmol/mol (6.8%, [6.40–7.70%]), and reduced urinary albumin/creatinine ratio from 67.8 (45.9–159.0) mg/mmol to 47.0 (26.0–93.6) mg/mmol. The untargeted metabolomics assay showed downregulated glycolysis and upregulated fatty acid oxidation. The targeted metabolomics assay revealed significant upregulation of glycine. The kidneys of db/db mice undergo significant metabolic reprogramming, with changes in sugar, lipid and amino acid metabolism; CANA regulated the metabolic reprogramming in the kidneys of db/db mice. In particular, the pathways for glycine, serine and threonine metabolism, as well as the metabolite of glycine, were significantly upregulated in CANA-treated kidneys. Glycine supplementation ameliorated renal lesions in db/db mice by inhibiting food intake, improving insulin sensitivity and reducing blood glucose levels. Glycine supplementation improved apoptosis of human proximal tubule cells via the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway. Conclusions/interpretation In conclusion, our study shows that CANA ameliorates DKD by inducing fasting-like and aestivation-like metabolic patterns. Furthermore, DKD was ameliorated by glycine supplementation, and the beneficial effects of glycine were probably due to the activation of the AMPK/mTOR pathway. Graphical Abstract
- Open Access
- 17 October 2023
- Published by IOP Publishing in Medical Engineering & Physics
- Vol. 121 (1) , 104064
Chromosome classification via deep learning and its application to patients with structural abnormalities of chromosomes
Karyotyping is an important technique in cytogenetic practice for the early diagnosis of genetic diseases. Clinical karyotyping is tedious, time-consuming, and error-prone. The objective of our study was to develop a single-stage deep convolutional neural networks (DCNN)-based model to automatically classify normal and abnormal chromosomes in an end-to-end manner. We analyzed 2,424 normal chromosomes and 544 abnormal chromosomes. A preliminary support vector machine (SVM) model was developed to evaluate the basic recognition performance on the dataset. A DCNN-based model was then proposed to process the same dataset. By utilizing the SVM model, the classification accuracy of 24 normal chromosomes was 86.01 %. The 32 types of normal and abnormal chromosomes got an accuracy of 85.37 %. The accuracy of the DCNN-based model performing the 24 normal chromosomal classification was 91.75 %. The accuracy of the 32 type classification was 87.76 %. To differentiate eight common structural abnormalities, we obtained accuracies that ranged from 90.84 % to 100 %, and the values of the AUC ranged from 91.81 % to 100 %. Our proposed DCNN-based model effectively performed the karyotype classification in an end-to-end manner. It had the competence to be used as a prediction tool for abnormal karyotype detection and screening in genetic diagnosis without initial feature extraction. We believe our work is meaningful for genetic triage management to lower the cost in clinical practice.
- 17 October 2023
- Published by IOP Publishing in Medical Engineering & Physics
- Vol. 121 (1) , 104064
Open AccessChromosome classification via deep learning and its application to patients with structural abnormalities of chromosomes
Karyotyping is an important technique in cytogenetic practice for the early diagnosis of genetic diseases. Clinical karyotyping is tedious, time-consuming, and error-prone. The objective of our study was to develop a single-stage deep convolutional neural networks (DCNN)-based model to automatically classify normal and abnormal chromosomes in an end-to-end manner. We analyzed 2,424 normal chromosomes and 544 abnormal chromosomes. A preliminary support vector machine (SVM) model was developed to evaluate the basic recognition performance on the dataset. A DCNN-based model was then proposed to process the same dataset. By utilizing the SVM model, the classification accuracy of 24 normal chromosomes was 86.01 %. The 32 types of normal and abnormal chromosomes got an accuracy of 85.37 %. The accuracy of the DCNN-based model performing the 24 normal chromosomal classification was 91.75 %. The accuracy of the 32 type classification was 87.76 %. To differentiate eight common structural abnormalities, we obtained accuracies that ranged from 90.84 % to 100 %, and the values of the AUC ranged from 91.81 % to 100 %. Our proposed DCNN-based model effectively performed the karyotype classification in an end-to-end manner. It had the competence to be used as a prediction tool for abnormal karyotype detection and screening in genetic diagnosis without initial feature extraction. We believe our work is meaningful for genetic triage management to lower the cost in clinical practice.
- 20 March 2023
- Published by Springer Nature in Endocrine
- Vol. 80 (2) , 336-345
Development and validation of a nomogram to estimate future risk of type 2 diabetes mellitus in adults with metabolic syndrome: prospective cohort study
Objectives To develop and validate the 4-year risk of type 2 diabetes mellitus among adults with metabolic syndrome. Design Retrospective cohort study of a large multicenter cohort with broad validation. Settings The derivation cohort was from 32 sites in China and the geographic validation cohort was from Henan population-based cohort study. Results 568 (17.63) and 53 (18.67%) participants diagnosed diabetes during 4-year follow-up in the developing and validation cohort, separately. Age, gender, body mass index, diastolic blood pressure, fasting plasma glucose and alanine aminotransferase were included in the final model. The area under curve for the training and external validation cohort was 0.824 (95% CI, 0.759–0.889) and 0.732 (95% CI, 0.594–0.871), respectively. Both the internal and external validation have good calibration plot. A nomogram was constructed to predict the probability of diabetes during 4-year follow-up, and on online calculator is also available for a more convenient usage (https://lucky0708.shinyapps.io/dynnomapp/). Conclusion We developed a simple diagnostic model to predict 4-year risk of type 2 diabetes mellitus among adults with metabolic syndrome, which is also available as web-based tools (https://lucky0708.shinyapps.io/dynnomapp/).
- 20 March 2023
- Published by Springer Nature in Endocrine
- Vol. 80 (2) , 336-345
Development and validation of a nomogram to estimate future risk of type 2 diabetes mellitus in adults with metabolic syndrome: prospective cohort study
Objectives To develop and validate the 4-year risk of type 2 diabetes mellitus among adults with metabolic syndrome. Design Retrospective cohort study of a large multicenter cohort with broad validation. Settings The derivation cohort was from 32 sites in China and the geographic validation cohort was from Henan population-based cohort study. Results 568 (17.63) and 53 (18.67%) participants diagnosed diabetes during 4-year follow-up in the developing and validation cohort, separately. Age, gender, body mass index, diastolic blood pressure, fasting plasma glucose and alanine aminotransferase were included in the final model. The area under curve for the training and external validation cohort was 0.824 (95% CI, 0.759–0.889) and 0.732 (95% CI, 0.594–0.871), respectively. Both the internal and external validation have good calibration plot. A nomogram was constructed to predict the probability of diabetes during 4-year follow-up, and on online calculator is also available for a more convenient usage (https://lucky0708.shinyapps.io/dynnomapp/). Conclusion We developed a simple diagnostic model to predict 4-year risk of type 2 diabetes mellitus among adults with metabolic syndrome, which is also available as web-based tools (https://lucky0708.shinyapps.io/dynnomapp/).
- Open Access
- 14 February 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1102777
Clinical characteristics of familial dysalbuminemic hyperthyroxinemia in Chinese patients and comparison of free thyroxine in three immunoassay methods
Objective: Familial dysalbuminemic hyperthyroxinemia (FDH) has not been thoroughly studied in the Chinese population to date. The clinical characteristics of FDH in Chinese patients were summarized, and the susceptibility of common free thyroxine (FT4) immunoassay methods was evaluated.Methods: The study included 16 affected patients from eight families with FDH admitted to the First Affiliated Hospital of Zhengzhou University. The published FDH patients of Chinese ethnicity were summarized. Clinical characteristics, genetic information, and thyroid function tests were analyzed. The ratio of FT4 to the upper limit of normal (FT4/ULN) in three test platforms was also compared in patients with R218H ALB mutation from our center.Results: The R218H ALB mutation was identified in seven families and the R218S in one family. The mean age of diagnosis was 38.4 ± 19.5 years. Half of the probands (4/8) were misdiagnosed as hyperthyroidism previously. The ratios of serum iodothyronine concentration to ULN in FDH patients with R218S were 8.05–9.74 for TT4, 0.68–1.28 for TT3, and 1.20–1.39 for rT3, respectively. The ratios in patients with R218H were 1.44 ± 0.15, 0.65 ± 0.14, and 0.77 ± 0.18, respectively. The FT4/ULN ratio detected using the Abbott I4000 SR platform was significantly lower than Roche Cobas e801 and Beckman UniCel Dxl 800 Access platforms (P < 0.05) in patients with R218H. In addition, nine Chinese families with FDH were retrieved from the literature, of which eight carried the R218H ALB mutation and one the R218S. The TT4/ULN of approximately 90% of patients (19/21) with R218H was 1.53 ± 0.31; the TT3/ULN of 52.4% of patients (11/21) was 1.49 ± 0.91. In the family with R218S, 45.5% of patients (5/11) underwent TT4 dilution test and the TT4/ULN was 11.70 ± 1.33 and 90.9% (10/11) received TT3 testing and the TT3/ULN was 0.39 ± 0.11.Conclusions: Two ALB mutations, R218S and R218H, were found in eight Chinese families with FDH in this study, and the latter may be a high-frequency mutation in this population. The serum iodothyronine concentration varies with different mutation forms. The rank order of deviation in measured versus reference FT4 values by different immunoassays (lowest to highest) was Abbott < Roche < Beckman in the FDH patients with R218H.
- 14 February 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1102777
Open AccessClinical characteristics of familial dysalbuminemic hyperthyroxinemia in Chinese patients and comparison of free thyroxine in three immunoassay methods
Objective: Familial dysalbuminemic hyperthyroxinemia (FDH) has not been thoroughly studied in the Chinese population to date. The clinical characteristics of FDH in Chinese patients were summarized, and the susceptibility of common free thyroxine (FT4) immunoassay methods was evaluated.Methods: The study included 16 affected patients from eight families with FDH admitted to the First Affiliated Hospital of Zhengzhou University. The published FDH patients of Chinese ethnicity were summarized. Clinical characteristics, genetic information, and thyroid function tests were analyzed. The ratio of FT4 to the upper limit of normal (FT4/ULN) in three test platforms was also compared in patients with R218H ALB mutation from our center.Results: The R218H ALB mutation was identified in seven families and the R218S in one family. The mean age of diagnosis was 38.4 ± 19.5 years. Half of the probands (4/8) were misdiagnosed as hyperthyroidism previously. The ratios of serum iodothyronine concentration to ULN in FDH patients with R218S were 8.05–9.74 for TT4, 0.68–1.28 for TT3, and 1.20–1.39 for rT3, respectively. The ratios in patients with R218H were 1.44 ± 0.15, 0.65 ± 0.14, and 0.77 ± 0.18, respectively. The FT4/ULN ratio detected using the Abbott I4000 SR platform was significantly lower than Roche Cobas e801 and Beckman UniCel Dxl 800 Access platforms (P < 0.05) in patients with R218H. In addition, nine Chinese families with FDH were retrieved from the literature, of which eight carried the R218H ALB mutation and one the R218S. The TT4/ULN of approximately 90% of patients (19/21) with R218H was 1.53 ± 0.31; the TT3/ULN of 52.4% of patients (11/21) was 1.49 ± 0.91. In the family with R218S, 45.5% of patients (5/11) underwent TT4 dilution test and the TT4/ULN was 11.70 ± 1.33 and 90.9% (10/11) received TT3 testing and the TT3/ULN was 0.39 ± 0.11.Conclusions: Two ALB mutations, R218S and R218H, were found in eight Chinese families with FDH in this study, and the latter may be a high-frequency mutation in this population. The serum iodothyronine concentration varies with different mutation forms. The rank order of deviation in measured versus reference FT4 values by different immunoassays (lowest to highest) was Abbott < Roche < Beckman in the FDH patients with R218H.
- Open Access
- 19 October 2022
- Published by Springer Nature in Research Square
Development and validation of a nomogram to estimate future risk of type 2 diabetes mellitus in adults with metabolic syndrome: prospective cohort study
Objectives: To develop and validate the 4-year risk of type 2 diabetes mellitus among adults with metabolic syndrome. Design: Retrospective cohort study of a large multicenter cohort with broad validation. Settings: The derivation cohort was from 32 sites in China and the geographic validation cohort was from Henan population-based cohort study. Results: 568(17.63%) and 53(18.67%) participants diagnosed diabetes during 4-year follow- up in the developing and validation cohort, separately. Age, gender, body mass index, diastolic blood pressure, fasting plasma glucose and alanine aminotransferase were included in the final model. The area under curve for the training and external validation cohort was 0.824(95%CI, 0.759-0.889) and 0.732(95%CI, 0.594-0.871), respectively. Both the internal and external validation have good calibration plot. A nomogram was constructed to predict the probability of diabetes during 4-year follow-up, and on online calculator is also available for a more convenient usage (https://lucky0708.shinyapps.io/dynnomapp/). Conclusion: We developed a simple diagnostic model to predict 4-year risk of type 2 diabetes mellitus among adults with metabolic syndrome, which is also available as web-based tools (https://lucky0708.shinyapps.io/dynnomapp/).
- 19 October 2022
- Published by Springer Nature in Research Square
Open AccessDevelopment and validation of a nomogram to estimate future risk of type 2 diabetes mellitus in adults with metabolic syndrome: prospective cohort study
Objectives: To develop and validate the 4-year risk of type 2 diabetes mellitus among adults with metabolic syndrome. Design: Retrospective cohort study of a large multicenter cohort with broad validation. Settings: The derivation cohort was from 32 sites in China and the geographic validation cohort was from Henan population-based cohort study. Results: 568(17.63%) and 53(18.67%) participants diagnosed diabetes during 4-year follow- up in the developing and validation cohort, separately. Age, gender, body mass index, diastolic blood pressure, fasting plasma glucose and alanine aminotransferase were included in the final model. The area under curve for the training and external validation cohort was 0.824(95%CI, 0.759-0.889) and 0.732(95%CI, 0.594-0.871), respectively. Both the internal and external validation have good calibration plot. A nomogram was constructed to predict the probability of diabetes during 4-year follow-up, and on online calculator is also available for a more convenient usage (https://lucky0708.shinyapps.io/dynnomapp/). Conclusion: We developed a simple diagnostic model to predict 4-year risk of type 2 diabetes mellitus among adults with metabolic syndrome, which is also available as web-based tools (https://lucky0708.shinyapps.io/dynnomapp/).